Literature DB >> 29618094

Clustering of Schizotypal Features in Unaffected First-Degree Relatives of Schizophrenia Patients.

Simon S Y Lui1,2, Karen S Y Hung2, Yi Wang1, Karen K Y Ho2, Hera K H Yeung2, Ya Wang1,3, Jia Huang1,3, Diane C Gooding4,5, Eric F C Cheung2, Raymond C K Chan1,3.   

Abstract

Meehl conceptualized schizotypy as the phenotypic manifestations of a neural integrative defect resulting from a schizophrenia diathesis. The majority of schizotypy studies recruited subjects from the general population and revealed a multidimensional construct. This 2-phase investigation first examined the clustering of schizotypy in 194 unaffected relatives of schizophrenia patients using the Chapman Psychosis Proneness scales and then directly compared the cognitive profiles of negative schizotypal individuals and positive schizotypal individuals with schizophrenia patients and controls. In the first phase, cluster analysis categorized 194 unaffected relatives of schizophrenia patients into positive schizotypy (n = 33), negative schizotypy (n = 66), mixed schizotypy (n = 27), and low schizotypy (n = 64). Positive schizotypal participants showed more self-report pleasure experiences than negative schizotypal participants, replicating earlier cluster analytic findings. In the second phase, 27 negative schizotypal individuals, 18 positive schizotypal individuals, 19 schizophrenia patients, and 29 controls were recruited. Although the groups were matched in terms of age, gender, and IQ, they differed significantly in cognitive profiles. While schizophrenia patients exhibited the broadest cognitive impairments, negative schizotypal participants exhibited visual memory, working memory, and verbal fluency impairments, and positive schizotypal participants exhibited logical memory, visual memory, working memory, and theory-of-mind impairments. Among people with familial risk of schizophrenia, individuals exhibiting positive rather than negative schizotypal features resembled schizophrenia patients in cognitive profiles. Using the psychometric-familial method to identify schizotypy, our findings support the heterogeneity of schizotypy as well as the potential utility of the positive schizotypy dimension in genetically high-risk individuals to predict the risk of developing schizophrenia.

Entities:  

Mesh:

Year:  2018        PMID: 29618094      PMCID: PMC6188519          DOI: 10.1093/schbul/sby035

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  50 in total

1.  Visuoconstructive performance, implicit hemispatial inattention, and schizotypy.

Authors:  Diane C Gooding; Jacqueline G Braun
Journal:  Schizophr Res       Date:  2004-06-01       Impact factor: 4.939

2.  The structure of schizotypy: a pilot multitrait twin study.

Authors:  K S Kendler; A L Ochs; A M Gorman; J K Hewitt; D E Ross; A F Mirsky
Journal:  Psychiatry Res       Date:  1991-01       Impact factor: 3.222

3.  Neurobiological changes of schizotypy: evidence from both volume-based morphometric analysis and resting-state functional connectivity.

Authors:  Yi Wang; Chao Yan; Da-zhi Yin; Ming-xia Fan; Eric F C Cheung; Christos Pantelis; Raymond C K Chan
Journal:  Schizophr Bull       Date:  2014-12-22       Impact factor: 9.306

4.  Thinking clearly about schizotypy: hewing to the schizophrenia liability core, considering interesting tangents, and avoiding conceptual quicksand.

Authors:  Mark F Lenzenweger
Journal:  Schizophr Bull       Date:  2015-03       Impact factor: 9.306

5.  A classification of hand preference by association analysis.

Authors:  M Annett
Journal:  Br J Psychol       Date:  1970-08

Review 6.  Neurocognitive impairment in deficit and non-deficit schizophrenia: a meta-analysis.

Authors:  E Bora; B Binnur Akdede; K Alptekin
Journal:  Psychol Med       Date:  2017-05-04       Impact factor: 7.723

7.  Contribution of specific cognitive dysfunction to people with schizotypal personality.

Authors:  Raymond C K Chan; Ya Wang; Chao Yan; Li-Ling Song; Yu-Na Wang; Yan-Fang Shi; Qi-Yong Gong; Eric F C Cheung
Journal:  Psychiatry Res       Date:  2010-07-27       Impact factor: 3.222

8.  Psychosis proneness scales in schizophrenia spectrum personality disorders: familial vs. nonfamilial samples.

Authors:  G Thaker; M Moran; H Adami; S Cassady
Journal:  Psychiatry Res       Date:  1993-01       Impact factor: 3.222

Review 9.  Intervention in individuals at ultra-high risk for psychosis: a review and future directions.

Authors:  Patrick D McGorry; Barnaby Nelson; G Paul Amminger; Andreas Bechdolf; Shona M Francey; Gregor Berger; Anita Riecher-Rössler; Joachim Klosterkötter; Stephan Ruhrmann; Frauke Schultze-Lutter; Merete Nordentoft; Ian Hickie; Philip McGuire; Michael Berk; Eric Y H Chen; Matcheri S Keshavan; Alison R Yung
Journal:  J Clin Psychiatry       Date:  2009-06-30       Impact factor: 4.384

Review 10.  A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder.

Authors:  J van Os; R J Linscott; I Myin-Germeys; P Delespaul; L Krabbendam
Journal:  Psychol Med       Date:  2008-07-08       Impact factor: 7.723

View more
  2 in total

1.  Handedness in bipolar disorders is associated with specific neurodevelopmental features: results of the BD-FACE cohort.

Authors:  Jasmina Mallet; Ophélia Godin; Nicolas Mazer; Yann Le Strat; Frank Bellivier; Raoul Belzeaux; Bruno Etain; Guillaume Fond; Sébastien Gard; Chantal Henry; Marion Leboyer; Pierre-Michel Llorca; Joséphine Loftus; Emilie Olié; Christine Passerieux; Mircea Polosan; Raymund Schwan; Paul Roux; Caroline Dubertret
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-08-10       Impact factor: 5.760

Review 2.  A systematic review and narrative synthesis of data-driven studies in schizophrenia symptoms and cognitive deficits.

Authors:  Tesfa Dejenie Habtewold; Lyan H Rodijk; Edith J Liemburg; Grigory Sidorenkov; H Marike Boezen; Richard Bruggeman; Behrooz Z Alizadeh
Journal:  Transl Psychiatry       Date:  2020-07-21       Impact factor: 6.222

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.